Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes-The RESTORE-G Real-World Study

被引：0
|
作者：
Candido, Riccardo
Nicolucci, Antonio
Larosa, Monica
Rossi, Maria Chiara
Napoli, Raffaele
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-87-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
87-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Ju-Ming Lu
    Advances in Therapy, 2019, 36 : 798 - 805
  • [22] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Lu, Ju-Ming
    ADVANCES IN THERAPY, 2019, 36 (04) : 798 - 805
  • [23] Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists
    Ji, Qiuhe
    CLINICAL THERAPEUTICS, 2017, 39 (06) : 1244 - 1264
  • [24] Effectiveness of glucagon-like peptide-1 agonists in type 2 diabetes
    Pavlicek, Vojtech
    DIABETOLOGIE, 2023, 19 (03): : 359 - 360
  • [25] It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
    Oberle, Megan M.
    Kelly, Aaron S.
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [26] The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
    Gameil, Mohammed Ali
    Yousef, Elshahat Ali Ahmed Mohamed
    Marzouk, Rehab Elsayed
    Emara, Mohamed H.
    Abdelkader, Abeer H.
    Salama, Rasha Ibrahim
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
  • [27] Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study
    Carretero Gomez, Juana
    Arevalo Lorido, Jose Carlos
    Gomez Huelgas, Ricardo
    Garcia de Lucas, Dolores
    Mateos Polo, Lourdes
    Varela Aguilar, Jose Manuel
    Segui Ripoll, Jose Miguel
    Ena, Javier
    CANADIAN JOURNAL OF DIABETES, 2019, 43 (03) : 186 - 192
  • [28] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [29] Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity
    Jensterle, Mojca
    Janez, Andrej
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 (06): : 599 - 608
  • [30] A real-world data analysis investigating the cardioprotective effects of glucagon-like peptide-1 receptor agonists among people with type 2 diabetes in England
    Connolly, D. L.
    Bain, S. C.
    Collins, E.
    Ren, H.
    Ming, S. W. Y.
    Davidson, J.
    EUROPEAN HEART JOURNAL, 2024, 45
12345